Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Larson RA, Chia YL, Granvil C, Guilhot F, Druker BJ, O'Brien SG, Baccarani M, Hughes TP, Nedelman JR, Wang YF

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: Blood: 51st Annual Meeting of the American Society of Hematology

Year of Conference: 2009

Pages: 872

ISSN: 0006-4971

Publisher: American Society of Hematology

Library holdings: Search Newcastle University Library for this item

ISBN:

ePrints